Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK and safety study of subcutaneous ublituximab at different injection sites and with autoinjector vs syringe in multiple sclerosis
2025-523757-33-00Phase 2Authorised
- Sponsor
- TG Therapeutics, Inc.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised trial of ublituximab in multiple sclerosis (MS) (2 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Incidence of treatment emergent adverse events (TEAE). Planned start Apr 2026; status: authorised.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-523757-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523757-33-00.